In 2018, if you want to know what's going on with the government, just check Twitter. It's a relatively new trend, adopted in earnest by the current administration and especially on display at agencies like the Food and Drug Administration. Commissioner Scott Gottlieb has averaged 400 posts per month on the social media platform, according to one analysis.
Yet the changes at the FDA extend much further than Twitter. Even before Gottlieb took the helm, the agency was providing guidance on some of pharma's most burning questions, as well as addressing pressing issues like drug pricing and development incentives.
In the content below, BioPharma Dive takes an in-depth look at how the regulatory landscape at the FDA has changed in recent years — and where it might be headed in the future.
-
FDA confronts its limits in push on drug pricing
Legally, regulating prices is outside of the FDA's purview. But that hasn't stopped Scott Gottlieb from taking a more vocal approach to the hot-button issue than past FDA chiefs. Read More→
-
FDA ups the ante for copycats, antibiotics, orphan drugs. But is it working?
Regulators are using incentives to spur development of much-needed drugs. The results so far have been mixed. Read More→
-
How Scott Gottlieb is upending FDA communication, one tweet at a time
The FDA commissioner has been relentless in pumping out tweets, statements and more. But how has that affected FDA communications and the agency overall? Read More→
-
Gottlieb teases guidance on continuous trials, touts surrogate endpoints
Gottlieb teases guidance on continuous trials, touts surrogate endpoints In a self-described "tweetorial," the FDA chief said modernizing clinical trials could help cut costs. Read More→
-
FDA permits more expansive communication between drugmakers, payers
New guidance sets out the agency's thinking on what information companies can share with insurers about their products, including for unapproved uses. Read More→